Lv1
30 积分 2024-06-05 加入
Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study
17天前
已完结
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial
17天前
已完结
Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials
20天前
已完结
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
20天前
已完结
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
1个月前
已完结
Consensus on the management of cutaneous adverse reactions to anti-tumor drugs
1个月前
已关闭
Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies
2个月前
已完结
VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma
2个月前
已完结
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
2个月前
已完结
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
2个月前
已完结
皖公网安备34019202002308
